B7-H3,a member of the B7 family within the immunoglobulin superfamily,is aberrantly expressed in tumor tissues and can be in-duced by immune cells,but is minimally expressed or not expressed in normal tissues.B7-H3 has gained attention for its ability to induce malignant behaviors in tumors and promote cancer progression through various complex pathways.Immunotherapy targeting B7-H3 has shown significant efficacy in clinical trials by modulating the immune system to enhance anti-tumor immune responses.We comprehens-ively summarize the abnormal expression and impact of B7-H3 in various human tumor types,and its role in immunotherapy,highlighting recent advances in clinical research targeting B7-H3.These findings suggest that B7-H3 holds great value as a future target for cancer dia-gnosis and treatment.

B7-H3,a member of the B7 family within the immunoglobulin superfamily,is aberrantly expressed in tumor tissues and can be in-duced by immune cells,but is minimally expressed or not expressed in normal tissues.B7-H3 has gained attention for its ability to induce malignant behaviors in tumors and promote cancer progression through various complex pathways.Immunotherapy targeting B7-H3 has shown significant efficacy in clinical trials by modulating the immune system to enhance anti-tumor immune responses.We comprehens-ively summarize the abnormal expression and impact of B7-H3 in various human tumor types,and its role in immunotherapy,highlighting recent advances in clinical research targeting B7-H3.These findings suggest that B7-H3 holds great value as a future target for cancer dia-gnosis and treatment.